Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
about
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineCpG Oligonucleotides as Cancer Vaccine AdjuvantsPeptide Vaccine: Progress and ChallengesAntigen-specific immunotherapy of cervical and ovarian cancerPerspectives for therapeutic HPV vaccine developmentPreexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell responseFusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responsesEpitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Perspectives for preventive and therapeutic HPV vaccines.Carrageenan as an adjuvant to enhance peptide-based vaccine potencyImmunotherapy for cervical cancer: Research status and clinical potentialLow-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responsesPeptides and peptidomimetics as immunomodulators.Recent advances in the development of breast cancer vaccines.TLR-based immune adjuvants.Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model.Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope HotspotControl of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agentsTherapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.Immunization with mutant HPV16 E7 protein inhibits the growth of TC-1 cells in tumor-bearing mice.Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in miceEffective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubesCytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.Peptide-based vaccines for cancer immunotherapy.Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope VaccineThe future of vaccines for cervical cancer.Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.Therapeutic Vaccine Strategies against Human Papillomavirus.Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Recent developments in human papillomavirus vaccines.Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.
P2860
Q26744087-404AA33F-F8E1-4FA6-8A10-22259F08A591Q26782583-971103A6-3DC9-4672-B14F-BE91E575CCFDQ26783826-3D36F20D-035A-4BA5-A777-D14C204DEB49Q26851329-490F9EEF-6F49-43AE-AB88-053767A3639FQ27488697-B952125A-3DD6-4C2D-A645-1570509B9161Q28069272-F8FB9B65-95B9-4BA1-98B9-5784BA807DDAQ30359962-CA4B096A-F410-485A-80DC-2A60871B8B18Q30425111-B7CFEE40-E0EE-4024-B682-D69A293809A3Q30538743-4D962021-3783-416E-8FA8-67D0A999E2F7Q31155155-6A061D76-50C8-4C1C-A4AC-B15175A3BD55Q33643966-15887A02-8498-4FDC-81DE-D212F6C11CEDQ33743226-0236F82F-4E43-4C26-9D3F-374930965738Q33863923-7092D8EE-D4F9-4974-B39C-6698A7F415E8Q33954123-4D199C15-7F04-47CC-A39F-27E3100B4917Q34011494-C8390AE3-A35D-4AB3-8804-8F79B7580681Q34012257-1A9440F5-16D1-4A8A-9EB1-9EE1DA5AE11FQ34033763-24B0ECF8-5CD7-4F5A-86E4-0E78B0374504Q34045548-04D69716-42DD-4F52-BC10-225BFEA86364Q34359984-5F003C1F-3BA7-4E49-A631-F29D6B86D2CDQ34379303-8099039A-D833-441D-AF01-7A68CF5D014DQ34400322-D9E23717-A52A-4914-AF35-96AA7D4E83C5Q34415859-866D7A26-B4F5-458D-B120-47B7DFDA3BDBQ34503830-C084FBD7-D691-4A76-A566-B51D1979DDB2Q34516610-1EF61529-2796-41AB-9D24-945726EA2436Q35077577-D44F74F3-855C-4341-ADE8-F3D94C18FA9BQ35102014-38A3B96C-CF76-4018-9B45-3DABC1C7552AQ35144042-F20928CC-EBBC-420A-A2BC-E6A2053C890AQ35167742-B2734383-4AD9-4BFF-8020-E27E44F73582Q35227905-7F6E2A6C-1698-4537-8C1F-C3516756941CQ35234708-94AB409F-8E3E-4775-8D42-6F9E4601E743Q35543857-C06B3826-975D-4DA2-AE4C-9738A35E8967Q35642602-BAFB42BC-9752-4F35-8DE8-DB14F9D9FBC6Q35681508-D3C28CBA-AAED-4B99-803C-1D918DA35547Q35782058-ED6D8691-1623-4C27-AE93-3ACE3A9D559DQ35805491-E2C2CA3D-0686-4912-9D4B-2B4009DA73EAQ35817394-8C416562-3630-4409-BF05-4B4D448A4046Q35826752-0650B615-E9B8-432E-8156-485E0C756F0AQ35838039-EBCC9BD3-23A4-4105-AF6E-1805338688D2Q35842528-1ECEDC19-BF68-4F44-821B-56D073CA0ADEQ35886752-8A190811-97B6-45A1-82D9-453CC266F7C5
P2860
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Established human papillomavir ...... accination with long peptides.
@en
type
label
Established human papillomavir ...... accination with long peptides.
@en
prefLabel
Established human papillomavir ...... accination with long peptides.
@en
P2093
P1476
Established human papillomavir ...... accination with long peptides.
@en
P2093
Cornelis J M Melief
Grayson B Lipford
Mark Johnson
Rienk Offringa
Sander Zwaveling
Sandra C Ferreira Mota
Sjoerd H van der Burg
P304
P356
10.4049/JIMMUNOL.169.1.350
P407
P577
2002-07-01T00:00:00Z